LGND at a glance
LIGAND PHARMACEUTICALS INC (LGND, SEC CIK 886163) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on October 30, 2026, an 8-K current report on October 29, 2026 and Form 4 insider filings as recently as November 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), LIGAND PHARMACEUTICALS INC (LGND) reported revenue of $268.1 million (up 60.4% from FY2024) and net income of $124.5 million. Diluted EPS was $6.13.
- As of September 30, 2026, 32 institutional investment managers tracked by SignalX reported holding LIGAND PHARMACEUTICALS INC (LGND) shares worth $3.4 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by KOZARICH JOHN W on November 12, 2026 of 500 shares at $325.00 per share.
- In the last 90 days, LGND insiders reported 0 open-market purchases ($0) and 40 open-market sales ($7.4M) on Form 4, a net sale of $7.4M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $268.1M
- +60.4% vs prior year
- Insiders · 90 days
- 0 buys · 40 sells
- Net −$7.4M
- 13F holders
- 32 funds
- $3.4B · +0 vs prior quarter
- Latest 8-K
- Oct 29, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: biopharmaceutical royalty company focused on capital deployment and licensing for diversified royalty streams from mid- to late-stage products
- New emphasis on NITRICIL platform acquired via Novan in 2023, supporting multiple royalty-bearing products including FDA-approved Zelsuvmi
- Strategic refinement since 2022 to a high-margin, low-infrastructure model after spinoffs of OmniAb, Pelican Expression, and Pelthos Therapeutics
- Invested $50 million in Castle Creek's D-Fi Phase 3 gene therapy and $25 million in Orchestra BioMed late-stage cardiology programs in 2025
- Expanded royalty portfolio to 12 major commercial royalties and over 90 additional programs, showing growing diversity and disciplined capital allocation
Risk Factors
- Regulatory risk: Section 162(m) limitation increased tax expense by $3.9 million (156%) in 2024 affecting effective tax rate
- Macroeconomic threat: $460 million 2030 Notes issued in August 2025 increases interest expense by $1.7 million (55%) vs prior year
- Operational risk: Deconsolidation of Novan acquisition payments from July 1, 2025 impacts interest accrued and financial reporting
- Market disruption risk: Unrealized fair value loss $5.1 million on Viking common stock in 2025 vs $9.0 million gain in 2024
- Financial risk: Concentration in equity method investments, e.g., $90.7 million gain from Pelthos stock fair value changes in 2025
Management Discussion & Analysis
- No forward-looking statements or guidance mentioned
AI summary of the LGND 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Q3 revenue and income $78.7M, down $36.7M or 32% YoY from $115.5M
- Net loss $28.5M vs net income $117.3M; operating costs 120% of revenue vs 52% YoY
- Best performer royalties $70.3M, up 51%; Filspari royalty revenue $16.8M vs $9.1M
- Cash, equivalents and short-term investments $447.4M vs $733.5M at December 31, 2025; operating cash flow $45.1M YTD
- XOMA acquisition and investments drove liquidity decline; management expects resources sufficient for at least twelve months
Risk Factors
- New acquisition risk triggered by July 14, 2026 XOMA Acquisition: integration may disrupt systems, personnel retention and royalty portfolio administration
- Royalty revenue risk: counterparties may buy out obligations below future royalties’ net present value
- Debt liquidity risk: 2030 Notes and 2031 Notes may require cash repurchases after specified events
- Financing risk: insufficient operating cash flow could force asset sales, debt restructuring or highly dilutive financing
- Litigation risk: potential XOMA Acquisition litigation disclosed, though not currently expected to be material
AI summary of the LGND 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Earnings release covers three and nine months ended September 30, 2026
- Exhibit 99.1 contains Ligand’s financial results and provides the substantive investor detail
Item EX-99.1: Item EX-99.1
- Q3 royalty revenue $70.3M, up 51% YoY, confirming XOMA assets and core products are accelerating recurring revenue
- Total revenue $78.7M, down 32% YoY, distorted by $53.1M of prior-year Pelthos-related income
Item 7.01: Regulation FD Disclosure
- Ligand financing agreement with AvenCell Therapeutics, a clinical-stage developer of controllable allogeneic CAR-T therapies
- Transaction provides AvenCell up to $47 million in financing
Item 7.01: Regulation FD Disclosure
- Ligand acquired royalty and milestone rights to Santen’s Ryjunea from Sydnexis
- $23 million upfront payment creates near-term cash outflow for future contingent revenue
AI summaries of LGND 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for LGND
Don't miss the next LGND filing
- Alerts as it files. A push when LGND files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut LGND, by share count.
- Ask anything. An AI agent that reads every LGND filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| KOZARICH JOHN W | Sell | Nov 12, 2026 | 500 | $325.00 |
| Zimmermann Martine | Sell | Nov 12, 2026 | 2,000 | $318.17 |
| Aryeh Jason | Sell | Nov 10, 2026 | 500 | $320.20 |
| Aryeh Jason | Sell | Nov 10, 2026 | 10 | $320.02 |
| Aryeh Jason | Sell | Nov 10, 2026 | 500 | $320.10 |
| Aryeh Jason | Sell | Nov 10, 2026 | 646 | $320.00 |
| Aryeh Jason | Sell | Nov 10, 2026 | 844 | $320.00 |
| Aryeh Jason | Sell | Nov 10, 2026 | 500 | $319.99 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $167.1M | $268.1M |
| Operating Income | - | -$22.6M | $41.0M |
| Net Income | $52.2M | -$4.0M | $124.5M |
| Op. Margin | - | -13.5% | 15.3% |
| Net Margin | - | -2.4% | 46.4% |
| Balance Sheet | |||
| Total Assets | $787.2M | $941.8M | $1.6B |
| Equity | - | $830.4M | $1.0B |
| ROE | - | -0.5% | 12.2% |
| Per Share | |||
| EPS | $2.94 | $-0.22 | $6.13 |
| Cash Flow | |||
| Operating CF | - | $97.0M | $49.4M |
| CapEx | $3.5M | $1.8M | $452K |
Source: XBRL data in LIGAND PHARMACEUTICALS INC (LGND)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate LGND share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 32 | $3.37B |
| Q2 2026 | 32 | $3.42B |
| Q1 2026 | 31 | $1.95B |
| Q4 2025 | 28 | $1.70B |
| Q3 2025 | 29 | $1.58B |
| Q2 2025 | 28 | $922.6M |
| Q1 2025 | 27 | $543.6M |
| Q4 2024 | 22 | $507.5M |
- Invesco Ltd+302.1K (+25%)
- Franklin Resources+160.3K (+21%)
- T. Rowe Price Group+76.0K (+83%)
- Wells Fargo & Co+73.3K (+128%)
- Bank of America Corp+72.4K (+43%)
- Dimensional Fund Advisors−66.1K (-15%)
- Prudential Financial−26.5K (-49%)
- Vanguard Portfolio Management LLC−26.3K (-2%)
- Northern Trust−11.6K (-5%)
- BNY Mellon−3.0K (-2%)
- FMR LLC (Fidelity)−762.8K
- Two Sigma Investments−18.8K
- Equitable Holdings Inc−9.3K
- OLD NATIONAL BANCORP /IN/−637
Source: 13F-HR filings on SEC EDGAR (aggregated from 229 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
LGND filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 16, 2026 | - | - | - |
| 4 | Nov 16, 2026 | - | - | - |
| 4 | Nov 12, 2026 | - | - | - |
| 4 | Nov 6, 2026 | - | - | - |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Nov 3, 2026 | - | - | - |
| 10-Q | Oct 30, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Oct 29, 2026 | - | Analysis | - |
| 4 | Oct 6, 2026 | - | - | - |
| 4 | Sep 24, 2026 | - | - | - |
| 8-K | Sep 24, 2026 | - | Analysis | - |
| 8-K | Sep 22, 2026 | - | Analysis | - |
| 4 | Sep 14, 2026 | - | - | - |
| 4 | Sep 8, 2026 | - | - | - |
| 8-K | Sep 2, 2026 | - | Analysis | - |
| 4 | Aug 14, 2026 | - | - | - |
| 4 | Aug 14, 2026 | - | - | - |
| SC 13G | Aug 13, 2026 | - | - | |
| 10-Q | Aug 7, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 4 | Aug 4, 2026 | - | - | - |
| 8-K | Jul 14, 2026 | - | Analysis | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
LGND SEC filings: frequently asked questions
Are LGND insiders buying or selling?
In the last 90 days, LIGAND PHARMACEUTICALS INC (LGND) officers, directors and 10% owners reported no open-market purchases and 40 open-market sales worth $7.4 million by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold LGND stock?
As of September 30, 2026, the largest LIGAND PHARMACEUTICALS INC (LGND) holders among the 13F filers tracked by SignalX were BlackRock ($972.2 million), Invesco Ltd ($469.7 million), Vanguard Portfolio Management LLC ($347.4 million), Franklin Resources ($288.4 million), Vanguard Capital Management LLC ($271.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was LGND's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), LIGAND PHARMACEUTICALS INC (LGND) reported revenue of $268.1 million (up 60.4% from FY2024) and net income of $124.5 million. Diluted EPS was $6.13. The figures come from the XBRL data in the 10-K.
What are the main risks in LGND's latest 10-K?
In the 10-K filed February 27, 2026, LIGAND PHARMACEUTICALS INC (LGND) flagged: Regulatory risk: Section 162(m) limitation increased tax expense by $3.9 million (156%) in 2024 affecting effective tax rate. Macroeconomic threat: $460 million 2030 Notes issued in August 2025 increases interest expense by $1.7 million (55%) vs prior year. (AI summary of the Risk Factors section.)
What did LGND report in its latest 8-K?
LIGAND PHARMACEUTICALS INC (LGND) filed an 8-K on October 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Earnings release covers three and nine months ended September 30, 2026.
What are the latest LGND SEC filings?
LIGAND PHARMACEUTICALS INC (LGND) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on October 30, 2026, an 8-K current report on October 29, 2026 and a Form 4 insider filing on November 16, 2026.
What is LGND's SEC CIK number?
LIGAND PHARMACEUTICALS INC (LGND)'s SEC Central Index Key (CIK) is 886163. EDGAR lists every LGND filing under that number.
Ask anything about LGND
The research agent reads LGND's filings, financials, insider trades and 13F holders, then answers with sources.